Dispersed and conserved hydrophobic residues of HIV-1 vif are essential for CBFβ recruitment and A3G suppression

Journal of Virology

Volumn 88, Issue 5, 2014, Pages 2555-2563

  Zhou, Xiaohong ^a,b,c   Han, Xue ^a,c   Zhao, Ke ^b   Du, Juan ^b   Evans, Sean L ^c   Wang, Hong ^b   Li, Peng ^b   Zheng, Wenwen ^b   Rui, Yajuan ^b   Kang, Jian ^b   Yu, Xiao Fang ^a,c  

^a TIANJIN UNIVERSITY   (China)

^b THE FIRST HOSPITAL OF JILIN UNIVERSITY   (China)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3F; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3G; CORE BINDING FACTOR BETA; CULLIN; CULLIN 5; PHENYLALANINE; TRYPTOPHAN; UNCLASSIFIED DRUG; VIF PROTEIN;

AMINO TERMINAL SEQUENCE; ARTICLE; COMPLEX FORMATION; CONTROLLED STUDY; HUMAN IMMUNODEFICIENCY VIRUS 1; HYDROPHOBICITY; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; SITE DIRECTED MUTAGENESIS; VIRUS CELL INTERACTION; VIRUS INFECTIVITY;

AMINO ACID SEQUENCE; CONSERVED SEQUENCE; CORE BINDING FACTOR BETA SUBUNIT; CYTIDINE DEAMINASE; HIV-1; HUMANS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; MUTATION; PROTEIN BINDING; PROTEIN INTERACTION DOMAINS AND MOTIFS; VIF GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS;

EID: 84896723296     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.03604-13     Document Type: Article

References (52)

1. UNAIDS. 2012. Global report: UNAIDS report on the global AIDS epidemic. UNAIDS, Geneva, Switzerland. http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2012/gr2012/20121120_UNAIDS_Global_Report_2012_en.pdf.
2. Greene WC, Debyser Z, Ikeda Y, Freed EO, Stephens E, Yonemoto W, Buckheit RW, Esté JA, Cihlar T. 2008. Novel targets for HIV therapy. Antiviral Res. 80:251-265.
3. Nathans R, Cao H, Sharova N, Ali A, Sharkey M, Stranska R, Stevenson M, Rana TM. 2008. Small-molecule inhibition of HIV-1 Vif. Nat. Biotechnol. 26:1187-1192. http://dx.doi.org/10.1038/nbt.1496.
4. Farrow MA, Sheehy AM. 2008. Vif and Apobec3G in the innate immune response to HIV: a tale of two proteins. Future Microbiol. 3:145-154. http//dx.doi.org/10.2217/17460913.3.2.145.
5. Harris RS, Bishop KN, Sheehy AM, Craig HM, Petersen-Mahrt SK, Watt IN, Neuberger MS, Malim MH. 2003. DNA deamination mediates innate immunity to retroviral infection. Cell 113:803-809. http://dx.doi.org/10.1016/S0092-8674(03)00423-9.
6. Sheehy AM, Gaddis NC, Choi JD, Malim MH. 2002. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 418:646-650. http://dx.doi.org/10.1038/nature00939.
7. Sheehy AM, Gaddis NC, Malim MH. 2003. The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat. Med. 9:1404-1407. http://dx.doi.org/10.1038/nm945.
8. Mariani R, Chen D, Schröfelbauer B, Navarro F, König R, Bollman B, Münk C, Nymark-McMahon H, Landau NR. 2003. Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif. Cell 114:21-31. http://dx.doi.org/10.1016/S0092-8674(03)00515-4.
9. Yu Y, Xiao Z, Ehrlich ES, Yu X, Yu X-F. 2004. Selective assembly of HIV-1 Vif-Cul5-ElonginB-ElonginC E3 ubiquitin ligase complex through a novel SOCS box and upstream cysteines. Genes Dev. 18:2867-2872. http://dx.doi.org/10.1101/gad.1250204.
10. Yu X, Yu Y, Liu B, Luo K, Kong W, Mao P, Yu XF. 2003. Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science 302:1056-1060. http://dx.doi.org/10.1126/science.1089591.
11. Yu X-F. 2006. Innate cellular defenses of APOBEC3 cytidine deaminases and viral counter-defenses. Curr. Opin. HIV AIDS 1:187-193. http://dx.doi.org/10.1097/01.COH.0000221590.03670.32.
12. Liu B, Sarkis PTN, Luo K, Yu Y, Yu X-F. 2005. Regulation of Apobec3F and human immunodeficiency virus type 1 Vif by Vif-Cul5-ElonB/C E3 ubiquitin ligase. J. Virol. 79:9579-9587. http://dx.doi.org/10.1128/JVI.79.15.9579-9587.2005.
13. Zhen A, Wang T, Zhao K, Xiong Y, Yu X-F. 2010. A single amino acid difference in human APOBEC3H variants determines HIV-1 Vif sensitivity. J. Virol. 84:1902-1911. http://dx.doi.org/10.1128/JVI.01509-09.
14. Gabuzda DH, Lawrence K, Langhoff E, Terwilliger E, Dorfman T, Haseltine WA, Sodroski J. 1992. Role of vif in replication of human immunodeficiency virus type 1 in CD4+ T lymphocytes. J. Virol. 66: 6489-6495.
15. Sakai H, Shibata R, Sakuragi J, Sakuragi S, Kawamura M, Adachi A. 1993. Cell-dependent requirement of human immunodeficiency virus type 1 Vif protein for maturation of virus particles. J. Virol. 67:1663-1666.
16. Zhou X, Evans SL, Han X, Liu Y, Yu X-F. 2012. Characterization of the interaction of full-length HIV-1 Vif protein with its key regulator CBFβ and CRL5 E3 ubiquitin ligase components. PLoS One 7:e33495. http://dx.doi.org/10.1371/journal.pone.0033495.
17. Zhang W, Du J, Evans SL, Yu Y, Yu XF. 2012. T-cell differentiation factor CBF-beta regulates HIV-1 Vif-mediated evasion of host restriction. Nature 481:376-379. http://dx.doi.org/10.1038/nature10718.
18. Salter JD, Lippa GM, Belashov IA, Wedekind JE. 2012. Core-binding factor β increases the affinity between human Cullin 5 and HIV-1 Vif within an E3 ligase complex. Biochemistry 51:8702-8704. http://dx.doi.org/10.1021/bi301244z.
19. Jager S, Kim DY, Hultquist JF, Shindo K, LaRue RS, Kwon E, Li M, Anderson BD, Yen L, Stanley D, Mahon C, Kane J, Franks-Skiba K, Cimermancic P, Burlingame A, Sali A, Craik CS, Harris RS, Gross JD, Krogan NJ. 2012. Vif hijacks CBF-beta to degrade APOBEC3G and promote HIV-1 infection. Nature 481:371-375. http://dx.doi.org/10.1038/nature10693.
20. Hultquist JF, McDougle RM, Anderson BD, Harris RS. 2012. HIV type 1 viral infectivity factor and the RUNX transcription factors interact with core binding factor beta on genetically distinct surfaces. AIDS Res. Hum. Retroviruses 28:1543-1551. http://dx.doi.org/10.1089/aid.2012.0142.
21. Hultquist JF, Binka M, LaRue RS, Simon V, Harris RS. 2012. Vif proteins of human and simian immunodeficiency viruses require cellular CBFβ to degrade APOBEC3 restriction factors. J. Virol. 86:2874-2877. http://dx.doi.org/10.1128/JVI.06950-11.
22. Kim DY, Kwon E, Hartley PD, Crosby DC, Mann S, Krogan NJ, Gross JD. 2013. CBFbeta stabilizes HIV Vif to counteract APOBEC3 at the expense of RUNX1 target gene expression. Mol. Cell 49:632-644. http://dx.doi.org/10.1016/j.molcel.2012.12.012.
23. Du J, Zhao K, Rui Y, Li P, Zhou X, Zhang W, Yu XF. 2013. Differential requirements for HIV-1 Vif-mediated APOBEC3G degradation and RUNX1-mediated transcription by core binding factor beta. J. Virol. 87: 1906-1911. http://dx.doi.org/10.1128/JVI.02199-12.
24. Mehle A, Goncalves J, Santa-Marta M, McPike M, Gabuzda D. 2004. Phosphorylation of a novel SOCS-box regulates assembly of the HIV-1 Vif-Cul5 complex that promotes APOBEC3G degradation. Genes Dev. 18:2861-2866. http://dx.doi.org/10.1101/gad.1249904.
25. Stanley BJ, Ehrlich ES, Short L, Yu Y, Xiao Z, Yu X-F, Xiong Y. 2008. Structural insight into the human immunodeficiency virus Vif SOCS box and its role in human E3 ubiquitin ligase assembly. J. Virol. 82:8656- 8663. http://dx.doi.org/10.1128/JVI.00767-08.
26. Bergeron JRC, Huthoff H, Veselkov DA, Beavil RL, Simpson PJ, Matthews SJ, Malim MH, Sanderson MR. 2010. The SOCS-box of HIV-1 Vif interacts with ElonginBC by induced-folding to recruit its Cul5- containing ubiquitin ligase complex. PLoS Pathog. 6:e1000925. http://dx.doi.org/10.1371/journal.ppat.1000925.
27. Shirakawa K, Takaori-Kondo A, Kobayashi M, Tomonaga M, Izumi T, Fukunaga K, Sasada A, Abudu A, Miyauchi Y, Akari H, Iwai K, Uchiyama T. 2006. Ubiquitination of APOBEC3 proteins by the Vif- Cullin5-ElonginB-ElonginC complex. Virology 344:263-266. http://dx.doi.org/10.1016/j.virol.2005.10.028.
28. Kobayashi M, Takaori-Kondo A, Miyauchi Y, Iwai K, Uchiyama T. 2005. Ubiquitination of APOBEC3G by an HIV-1 Vif-Cullin5-Elongin B-Elongin C complex is essential for Vif function. J. Biol. Chem. 280: 18573-18578. http://dx.doi.org/10.1074/jbc.C500082200.
29. Wolfe LS, Stanley BJ, Liu C, Eliason WK, Xiong Y. 2010. Dissection of the HIV Vif interaction with human E3 ubiquitin ligase. J. Virol. 84:7135- 7139. http://dx.doi.org/10.1128/JVI.00031-10.
30. Xiao Z, Xiong Y, Zhang W, Tan L, Ehrlich E, Guo D, Yu X-F. 2007. Characterization of a novel Cullin5 binding domain in HIV-1 Vif. J. Mol. Biol. 373:541-550. http://dx.doi.org/10.1016/j.jmb.2007.07.029.
31. Xiao Z, Ehrlich E, Luo K, Xiong Y, Yu X-F. 2007. Zinc chelation inhibits HIV Vif activityandliberates antiviral function of the cytidinedeaminaseAPOBEC3G. FASEB J. 21:217-222. http://dx.doi.org/10.1096/fj.06-6773com.
32. Xiao Z, Ehrlich E, Yu Y, Luo K, Wang T, Tian C, Yu X-F. 2006. Assembly of HIV-1 Vif-Cul5 E3 ubiquitin ligase through a novel zincbinding domain-stabilized hydrophobic interface in Vif. Virology 349: 290-299. http://dx.doi.org/10.1016/j.virol.2006.02.002.
33. Paul I, Cui J, Maynard EL. 2006. Zinc binding to the HCCH motif of HIV-1 virion infectivity factor induces a conformational change that mediates protein-protein interactions. Proc. Natl. Acad. Sci. U. S. A. 103: 18475-18480. http://dx.doi.org/10.1073/pnas.0604150103.
34. Reingewertz TH, Shalev DE, Friedler A. 2010. Structural disorder in the HIV-1 Vif protein and interaction-dependent gain of structure. Protein Pept. Lett. 17:988-998. http://dx.doi.org/10.2174/092986610791498876.
35. Giri K, Maynard EL. 2009. Conformational analysis of a peptide approximating the HCCH motif in HIV-1 Vif. Biopolymers 92:417-425. http://dx.doi.org/10.1002/bip.21209.
36. Giri K, Scott RA, Maynard EL. 2009. Molecular structure and biochemical properties of the HCCH-Zn2+ site in HIV-1 Vif. Biochemistry 48: 7969-7978. http://dx.doi.org/10.1021/bi900677w.
37. Mehle A, Thomas ER, Rajendran KS, Gabuzda D. 2006. A zinc-binding region in Vif binds Cul5 and determines cullin selection. J. Biol. Chem. 281:17259-17265. http://dx.doi.org/10.1074/jbc.M602413200.
38. Luo K, Xiao Z, Ehrlich E, Yu Y, Liu B, Zheng S, Yu X-F. 2005. Primate lentiviral virion infectivity factors are substrate receptors that assemble with cullin 5-E3 ligase through a HCCH motif to suppress APOBEC3G. Proc. Natl. Acad. Sci. U. S. A. 102:11444-11449. http://dx.doi.org/10.1073/pnas.0502440102.
39. Chen G, He Z, Wang T, Xu R, Yu X-F. 2009. A patch of positively charged amino acids surrounding the human immunodeficiency virus type 1 Vif SLVx4Yx9Y motif influences its interaction with APOBEC3G. J. Virol. 83:8674-8682. http://dx.doi.org/10.1128/JVI.00653-09.
40. Dang Y, Wang X, Zhou T, York IA, Zheng Y-H. 2009. Identification of a novel WxSLVK motif in the N terminus of human immunodeficiency virus and simian immunodeficiency virus Vif that is critical for APOBEC3G and APOBEC3F neutralization. J. Virol. 83:8544-8552. http://dx.doi.org/10.1128/JVI.00651-09.
41. Dang Y, Davis RW, York IA, Zheng Y-H. 2010. Identification of 81LGxGxx IxW89and171EDRW174domainsfromhumanimmunodeficiencyvirus type 1 Vif that regulate APOBEC3G and APOBEC3F neutralizing activity. J. Virol. 84: 5741-5750. http://dx.doi.org/10.1128/JVI.00079-10.
42. Zhang W, Chen G, Niewiadomska AM, Xu R, Yu X-F. 2008. Distinct determinants in HIV-1 Vif and human APOBEC3 proteins are required for the suppression of diverse host anti-viral proteins. PLoS One 3:e3963. http://dx.doi.org/10.1371/journal.pone.0003963.
43. Russell RA, Smith J, Barr R, Bhattacharyya D, Pathak VK. 2009. Distinct domains within APOBEC3G and APOBEC3F interact with separate regions of human immunodeficiency virus type 1 Vif. J. Virol. 83: 1992-2003. http://dx.doi.org/10.1128/JVI.01621-08.
44. Russell RA, Pathak VK. 2007. Identification of two distinct human immunodeficiency virus type 1 Vif determinants critical for interactions with human APOBEC3G and APOBEC3F. J. Virol. 81:8201-8210. http://dx.doi.org/10.1128/JVI.00395-07.
45. Cadima-Couto I, Saraiva N, Santos ACC, Goncalves J. 2011. HIV-1 Vif interaction with APOBEC3 deaminases and its characterization by a new sensitive assay. J. Neuroimmune Pharmacol. 6:296-307. http://dx.doi.org/10.1007/s11481-011-9258-7.
46. Tian C, Yu X, Zhang W, Wang T, Xu R, Yu X-F. 2006. Differential requirement for conserved tryptophans in human immunodeficiency virus type 1 Vif for the selective suppression of APOBEC3G and APOBEC3F. J. Virol. 80:3112-3115. http://dx.doi.org/10.1128/JVI.80.6.3112-3115.2006.
47. Schröfelbauer B, Senger T, Manning G, Landau NR. 2006. Mutational alteration of human immunodeficiency virus type 1 Vif allows for functional interaction with nonhuman primate APOBEC3G. J. Virol. 80: 5984-5991. http://dx.doi.org/10.1128/JVI.00388-06.
48. Simon V, Zennou V, Murray D, Huang Y, Ho DD, Bieniasz PD. 2005. Natural variation in Vif: differential impact on APOBEC3G/3F and a potential role in HIV-1 diversification. PLoS Pathog. 1:e6. http://dx.doi.org/10.1371/journal.ppat.0010006.
49. Marin M, Rose KM, Kozak SL, Kabat D. 2003. HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation. Nat. Med. 9:1398-1403. http://dx.doi.org/10.1038/nm946.
50. He Z, Zhang W, Chen G, Xu R, Yu X-F. 2008. Characterization of conserved motifs in HIV-1 Vif required for APOBEC3G and APOBEC3F interaction. J. Mol. Biol. 381:1000-1011. http://dx.doi.org/10.1016/j.jmb.2008.06.061.
51. Pery E, Rajendran KS, Brazier AJ, Gabuzda D. 2009. Regulation of APOBEC3 proteins by a novel YXXL motif in human immunodeficiency virus type 1 Vif and simian immunodeficiency virus SIVagm Vif. J. Virol. 83:2374-2381. http://dx.doi.org/10.1128/JVI.01898-08.
52. Wei W, Guo H, Han X, Liu X, Zhou X, Zhang W, Yu XF. 2012. A novel DCAF1-binding motif required for Vpx-mediated degradation of nuclear SAMHD1 and Vpr-induced G2 arrest. Cell. Microbiol. 14:1745-1756. http://dx.doi.org/10.1111/j.1462-5822.2012.01835.x.